Veterinary Infectious Disease Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Immunodiagnostic,Molecular Diagnostic,Others), By Application (Reference Laboratories,Veterinary Laboratories and Clinics,Point of Care/In House Testing,Research Institutes and Universities), Regional Insights and Forecast to 2035

Veterinary Infectious Disease Diagnostics Market Overview

The global Veterinary Infectious Disease Diagnostics Market is forecast to expand from USD 2465.14 million in 2026 to USD 2659.39 million in 2027, and is expected to reach USD 4878.42 million by 2035, growing at a CAGR of 7.88% over the forecast period.

The global Veterinary Infectious Disease Diagnostics Market saw estimated market activity of roughly USD 2.4–2.7 billion in recent year assessments, with veterinary reference labs performing tens of millions of infectious disease assays annually across companion animals and livestock. Molecular diagnostics (PCR-based) represent about 25–35% of infectious-disease testing volume in advanced markets, while immunodiagnostics (ELISA, lateral flow) account for 45–55% of test units globally. Companion-animal testing constitutes approximately 50–60% of infectious-testing demand, with livestock and poultry testing comprising 30–40% and equine/specialty species the remainder. The Veterinary Infectious Disease Diagnostics Market Analysis highlights expanding point-of-care instrument installs and rising multiplex assay adoption.

In the United States, veterinary infectious disease diagnostics are driven by a companion animal population exceeding 160 million (dogs and cats combined) and more than 130,000 licensed veterinarians; veterinary clinics and hospitals logged >250 million patient visits annually in recent data points. U.S. veterinary reference laboratories process millions of infectious disease samples per year, with in-clinic point-of-care (POC) test kits used in >70% of small-animal practices for rapid screening. The U.S. market shows strong penetration of in-house analyzers (an estimated 40–50% of clinics use at least one automation platform), and reference-lab confirmatory testing remains the standard for complex molecular assays.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Global veterinary clinics and labs conduct over 60 million infectious disease tests annually, driven by more than 160 million companion animals and increasing livestock surveillance worldwide.
• Major Market Restraint: Diagnostic test costs range from $10–300 per sample, limiting access for smaller farms and clinics, especially in developing regions.
• Emerging Trends: More than 30 multiplex PCR panels and 200+ rapid immunodiagnostic kits were introduced globally between 2023 and 2025, supporting faster and broader disease detection.
• Regional Leadership: North America leads the market with over 130,000 licensed veterinarians and 50+ reference laboratories handling millions of diagnostic samples annually.
• Competitive Landscape: Around 10–15 major players dominate the market, with IDEXX Laboratories and Biomérieux collectively managing testing solutions across 100+ countries.
• Market Segmentation: Immunodiagnostic assays account for roughly 45–55% of total test volume, while molecular diagnostic methods perform over 10 million PCR-based tests each year.
• Recent Development: Over 150 new veterinary diagnostic products were launched globally between 2023 and 2025, including cloud-enabled analyzers and portable PCR devices adopted by >5,000 veterinary sites.

Veterinary Infectious Disease Diagnostics Market Latest Trends

Current Veterinary Infectious Disease Diagnostics Market Trends include rapid expansion of molecular multiplex platforms and POC immunoassays; industry data indicates >30 multiplex panels introduced in the last 36 months and >200 new rapid-test SKUs launched globally over two years. Reference laboratories now run >10 million molecular infectious assays annually in aggregate across leading operators, while clinic-level lateral-flow and ELISA tests account for tens of millions of single-use devices distributed each year. The companion animal segment drives much of the high-frequency testing: U.S. clinics perform routine screening for core pathogens (e.g., parvovirus, distemper, FeLV/FIV) in >25 million visits per year.

Veterinary Infectious Disease Diagnostics Market Dynamics

DRIVER

"Rising pet ownership, intensifying biosecurity and surveillance."

Companion animal populations in key markets are significant: U.S. dog and cat populations exceed 160 million animals, Europe has >200 million pets, and Asia-Pacific pet numbers are growing by millions each year, driving clinic visits and test demand. Livestock and poultry sectors maintain huge sample volumes—global poultry inventories exceed 20 billion birds, and national surveillance programs collect thousands of samples weekly for avian influenza and other notifiable diseases. 

RESTRAINT

"Cost sensitivity in field, limited reimbursement, and fragmented purchasing."

Many veterinary clients pay out of pocket and are price-sensitive: a point-of-care rapid test typically retails for USD 10–40 per kit, while confirmatory molecular assays at reference labs cost USD 50–300 per sample depending on complexity. For production-animal testing, per-animal testing economics limit routine use of high-cost molecular panels in smallhold farms; pooled testing strategies (pools of 5–20 specimens) are commonly used to reduce per-animal expense. 

OPPORTUNITY

"Point-of-care automation, multiplex assays, and surveillance contracts."

POC analyzers with onboard PCR or isothermal capability are being deployed: several manufacturers reported >5,000 POC units placed in clinics and farms combined, enabling on-site molecular detection within 20–90 minutes. Multiplex panels that detect 4–12 pathogens per run reduce sample handling and deliver higher value per test; reference labs and large veterinary networks place standing orders for thousands of such tests per month.

CHALLENGE

"Validation and standardization across species and sample matrices."

Validating assays for multiple species (canine, feline, bovine, porcine, avian, equine) and diverse sample matrices (blood, swabs, feces, tissues) is complex; many assays require species-specific sensitivity and specificity data across 100s of samples. Cross-reactivity and differing pathophysiology mean that an assay validated in one species may need dozens more experiments for another, extending development by 6–18 months. 

Veterinary Infectious Disease Diagnostics Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Veterinary Infectious Disease Diagnostics Market segments by type (Immunodiagnostic, Molecular Diagnostic, Others) and application (Reference Laboratories, Veterinary Laboratories & Clinics, Point-of-Care/In-House Testing, Research Institutes & Universities).

BY TYPE

Immunodiagnostic: Immunodiagnostic tests (ELISA, lateral-flow rapid tests, immunofluorescence) account for the majority of unit volume due to low per-test cost and fast results; global shipments exceed tens of millions of lateral-flow cassettes annually for common pathogens such as parvovirus, canine influenza, and feline retroviruses. ELISA plate-based assays remain staples in reference labs with throughput of >500–5,000 samples per plate run on automated ELISA systems.

The Immunodiagnostic segment is estimated at USD 1,020 million in 2025, holding approximately 44.7% market share, projected to grow at a CAGR of 7.7%, supported by rapid detection kits and ELISA-based assays for veterinary infections.

Top 5 Major Dominant Countries in the Immunodiagnostic Segment

• United States: Market size USD 360 million, share 35.3%, CAGR 7.6%, high pet ownership and livestock testing drive immunodiagnostic demand.
• Germany: Valued at USD 140 million, share 13.7%, CAGR 7.5%, advanced veterinary laboratories and stringent regulations fuel segment growth.
• China: Market size USD 120 million, share 11.8%, CAGR 7.8%, increasing livestock and poultry production supports immunodiagnostic adoption.
• France: Valued at USD 100 million, share 9.8%, CAGR 7.7%, commercial veterinary labs and research institutes drive market demand.
• India: Market size USD 80 million, share 7.8%, CAGR 8%, rising livestock health awareness and veterinary infrastructure expansion support growth.

Molecular Diagnostic: Molecular diagnostics (real-time PCR, multiplex PCR, isothermal amplification, sequencing) represent a rapidly expanding portion of Veterinary Infectious Disease Diagnostics Market value and complexity. Leading reference laboratories run >10 million molecular tests annually across major geographies for pathogens like Leptospira, Brucella, PRRSV, and avian influenza.

The Molecular Diagnostic segment is projected at USD 850 million in 2025, holding 37.2% market share, with a CAGR of 8%, driven by PCR and nucleic acid-based detection for rapid identification of infectious diseases.

Top 5 Major Dominant Countries in the Molecular Diagnostic Segment

• United States: Market size USD 300 million, share 35.3%, CAGR 7.9%, increasing adoption of PCR-based veterinary testing supports growth.
• Germany: Valued at USD 120 million, share 14.1%, CAGR 7.8%, advanced veterinary diagnostic labs expand molecular testing segment.
• China: Market size USD 110 million, share 12.9%, CAGR 8.2%, rising livestock and companion animal testing drives adoption.
• France: Valued at USD 80 million, share 9.4%, CAGR 7.8%, research institutes and commercial labs enhance market demand.
• Brazil: Market size USD 70 million, share 8.2%, CAGR 8%, growing livestock and poultry testing requirements support segment growth.

Others: The “Others” category includes culture, biochemical methods, microscopy, seroneutralization, and pathogen isolation; together these account for the remaining ~10–20% of diagnostic units but are critical for confirmatory testing and antimicrobial susceptibility. Culture workflows in veterinary microbiology labs process hundreds to thousands of plates per week in high-volume facilities, with turnaround times commonly 48–120 hours.

The Others segment is estimated at USD 415.07 million in 2025, holding 18.1% market share, projected to grow at a CAGR of 7.6%, including serological tests, culture-based methods, and emerging diagnostic technologies.

Top 5 Major Dominant Countries in the Others Segment

• United States: Market size USD 155 million, share 37.3%, CAGR 7.5%, traditional and emerging diagnostic adoption supports segment expansion.
• Germany: Valued at USD 55 million, share 13.3%, CAGR 7.6%, veterinary labs using culture and serology fuel growth.
• China: Market size USD 50 million, share 12%, CAGR 7.7%, livestock and poultry testing drives demand.
• France: Valued at USD 35 million, share 8.4%, CAGR 7.5%, research institutes support development of emerging tests.
• India: Market size USD 30 million, share 7.2%, CAGR 7.8%, expanding veterinary infrastructure boosts segment growth.

BY APPLICATION 

Reference Laboratories: Reference laboratories handle high-throughput, high-complexity infectious disease diagnostics; top global veterinary reference labs process hundreds of thousands to millions of samples annually. These labs operate automated qPCR instruments with capacities of >10,000 tests per week per site, and many maintain cold-chain logistics to receive samples from hundreds of clinics.

The Reference Laboratories segment is valued at USD 820 million in 2025, growing at a CAGR of 7.7%, driven by specialized diagnostic centers and high-volume testing for veterinary infectious diseases.

Top 5 Major Dominant Countries in Reference Laboratories

• United States: Market size USD 300 million, share 36.6%, CAGR 7.6%, advanced reference labs cater to pet and livestock testing needs.
• Germany: Valued at USD 110 million, share 13.4%, CAGR 7.5%, commercial reference labs enhance adoption of advanced diagnostics.
• China: Market size USD 100 million, share 12.2%, CAGR 7.8%, centralized testing facilities support livestock and poultry disease monitoring.
• France: Valued at USD 85 million, share 10.4%, CAGR 7.7%, reference laboratories drive molecular and immunodiagnostic adoption.
• Brazil: Market size USD 65 million, share 7.9%, CAGR 7.9%, growing livestock testing requirement strengthens reference lab segment.

Veterinary Laboratories and Clinics: Veterinary clinics and in-house hospital labs use POC immunodiagnostics and smaller analyzers that perform hematology, chemistry, and select infectious assays; estimates indicate 40–50% of clinics own at least one in-house analyzer. Rapid lateral-flow tests are used in >60% of small-animal visits for frontline screening, while mid-size practices may run 10–200 automatic immunoassays monthly.

The Veterinary Laboratories and Clinics segment is projected at USD 725 million in 2025, with a CAGR of 8%, fueled by routine testing and growing veterinary healthcare infrastructure globally.

Top 5 Major Dominant Countries in Veterinary Laboratories and Clinics

• United States: Market size USD 270 million, share 37.2%, CAGR 7.9%, extensive clinic networks drive market adoption.
• Germany: Valued at USD 100 million, share 13.8%, CAGR 7.8%, veterinary clinics perform immunodiagnostic and molecular testing.
• China: Market size USD 90 million, share 12.4%, CAGR 8.1%, expanding pet ownership and livestock farms fuel growth.
• France: Valued at USD 80 million, share 11%, CAGR 7.8%, private veterinary laboratories drive testing adoption.
• India: Market size USD 60 million, share 8.3%, CAGR 8.2%, growing veterinary clinics support market growth.

Point of Care / In-House Testing: Point-of-care (POC) and in-house testing is a major driver of rapid diagnostics adoption. Rapid immunoassays provide results within 5–30 minutes, enabling immediate clinical decisions; POC molecular devices deliver answers in 20–90 minutes.

The Point of Care/In House Testing segment is estimated at USD 430 million in 2025, with a CAGR of 8.1%, driven by rapid diagnostic kits and on-site veterinary testing solutions.

Top 5 Major Dominant Countries in Point of Care/In House Testing

• United States: Market size USD 160 million, share 37.2%, CAGR 8%, increasing adoption of portable diagnostic kits supports growth.
• Germany: Valued at USD 55 million, share 12.8%, CAGR 7.9%, veterinary hospitals use rapid testing kits on-site.
• China: Market size USD 50 million, share 11.6%, CAGR 8.2%, livestock and pet veterinary demand drives adoption.
• France: Valued at USD 40 million, share 9.3%, CAGR 8%, clinics adopt POC diagnostic solutions for faster results.
• Brazil: Market size USD 35 million, share 8.1%, CAGR 8.1%, growing animal husbandry sector supports point-of-care adoption.

"Research Institutes and Universities: "Research institutes and universities perform specialized diagnostic testing, method development, and epidemiologic surveillance; they run multiplex PCRs, serology panels, and NGS-based pathogen discovery studies on sample sets often exceeding 1,000–10,000 specimens per project.

The Research Institutes and Universities segment is projected at USD 310 million in 2025, growing at a CAGR of 7.9%, driven by veterinary research and development activities globally.

Top 5 Major Dominant Countries in Research Institutes and Universities

• United States: Market size USD 120 million, share 38.7%, CAGR 7.8%, veterinary R&D programs increase diagnostic kit usage.
• Germany: Valued at USD 45 million, share 14.5%, CAGR 7.7%, academic research in veterinary diagnostics drives adoption.
• China: Market size USD 40 million, share 12.9%, CAGR 8%, universities perform molecular and immunodiagnostic research.
• France: Valued at USD 35 million, share 11.3%, CAGR 7.9%, research institutes contribute to emerging diagnostics development.
• India: Market size USD 30 million, share 9.7%, CAGR 8.1%, veterinary research programs support diagnostic market growth.

Veterinary Infectious Disease Diagnostics Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Veterinary Infectious Disease Diagnostics Market performance varies: North America leads in per-capita diagnostics utilization and reference lab capacity with >30% of global molecular tests; Europe has strong surveillance networks and veterinary lab density, performing >20% of global confirmatory testing; Asia-Pacific shows fastest test-volume growth with expanding farm surveillance and companion-animal testing representing >25% of test units; Middle East & Africa remain developing markets but are increasing capacity with national surveillance programs processing thousands of samples annually.

NORTH AMERICA

North America accounts for a leading share of veterinary infectious disease diagnostic activity: the region hosts >130,000 licensed veterinarians in the U.S. and processes millions of diagnostic tests annually across reference and in-house labs. IDEXX and other major reference providers maintain networks of >50–100 reference laboratories and send-out logistics servicing thousands of clinics. Companion-animal testing comprises approximately 60% of diagnostic volume in the region, driven by high pet ownership—U.S. dog and cat populations exceed 160 million combined—and frequent veterinary visits, measured in the hundreds of millions annually.

North America market is estimated at USD 970 million in 2025, share 42.5%, CAGR 7.7%, driven by the United States and Canada with high adoption of veterinary diagnostics across livestock, companion animals, and research facilities.

North America – Major Dominant Countries

• United States: Market size USD 900 million, share 92.8%, CAGR 7.7%, advanced veterinary infrastructure and high pet ownership support market growth.
• Canada: Valued at USD 60 million, share 6.2%, CAGR 7.6%, livestock and companion animal diagnostic adoption expands segment.
• Mexico: Market size USD 5 million, share 0.5%, CAGR 7.8%, niche veterinary testing supports adoption.
• Puerto Rico: Valued at USD 3 million, share 0.3%, CAGR 7.7%, limited veterinary diagnostics usage contributes marginally.
• Cuba: Market size USD 2 million, share 0.2%, CAGR 7.6%, minimal market penetration supports adoption.

EUROPE

Europe maintains high diagnostic density and robust laboratory networks, with national reference labs in most countries processing tens of thousands of infectious disease tests annually. European companion-animal clinical testing is significant—several national markets exceed 10–20 million diagnostic encounters per year—while production-animal surveillance mandates frequent sampling in poultry and swine sectors, often amounting to thousands of monthly tests per region.

Europe market is projected at USD 630 million in 2025, share 27.6%, CAGR 7.8%, driven by Germany, France, UK, and Italy with widespread veterinary laboratories and research institutions.

Europe – Major Dominant Countries

• Germany: Market size USD 200 million, share 31.7%, CAGR 7.7%, advanced labs and research institutes drive adoption.
• France: Valued at USD 120 million, share 19%, CAGR 7.8%, veterinary hospitals and laboratories contribute to growth.
• United Kingdom: Market size USD 100 million, share 15.9%, CAGR 7.8%, pet ownership and commercial labs support market expansion.
• Italy: Valued at USD 85 million, share 13.5%, CAGR 7.7%, livestock diagnostic testing drives segment growth.
• Spain: Market size USD 70 million, share 11.1%, CAGR 7.8%, research institutes and clinics fuel adoption.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region for Veterinary Infectious Disease Diagnostics Market volume, driven by rising pet ownership, expanding livestock production, and increased investment in diagnostic infrastructure. China and India have burgeoning companion-animal populations (tens of millions each) and large livestock sectors—with poultry inventories in some countries exceeding billions of birds—resulting in heavy testing demand. 

Asia market is estimated at USD 540 million in 2025, share 23.6%, CAGR 8%, driven by China, India, Japan, and South Korea with increasing livestock, poultry, and companion animal testing requirements.

Asia – Major Dominant Countries

• China: Market size USD 180 million, share 33.3%, CAGR 8.1%, livestock testing and companion animal diagnostics drive growth.
• India: Valued at USD 140 million, share 25.9%, CAGR 8.2%, expanding veterinary infrastructure supports adoption.
• Japan: Market size USD 100 million, share 18.5%, CAGR 7.9%, high pet ownership and research institutes fuel growth.
• South Korea: Valued at USD 60 million, share 11.1%, CAGR 8%, veterinary labs adopt advanced diagnostic technologies.
• Thailand: Market size USD 35 million, share 6.5%, CAGR 7.9%, livestock testing requirements drive market expansion.

MIDDLE EAST & AFRICA

Middle East & Africa currently contribute a smaller share of global veterinary infectious diagnostics but show growing surveillance investment. Many countries operate national reference labs that process thousands of samples annually for transboundary animal diseases and zoonoses; Gulf countries often import advanced diagnostic platforms and carry out high-volume testing for imported livestock and large-scale poultry operations, with single projects sometimes exceeding 10,000 tests. 

Middle East & Africa market is projected at USD 145 million in 2025, share 6.3%, CAGR 7.7%, driven by UAE, Saudi Arabia, South Africa, and Egypt with growing adoption of veterinary diagnostics.

Middle East & Africa – Major Dominant Countries

• UAE: Market size USD 50 million, share 34.5%, CAGR 7.8%, commercial veterinary labs and livestock testing support growth.
• Saudi Arabia: Valued at USD 40 million, share 27.6%, CAGR 7.7%, increasing pet and livestock diagnostics adoption drives segment expansion.
• South Africa: Market size USD 25 million, share 17.2%, CAGR 7.6%, veterinary clinics and research institutes support market demand.
• Egypt: Valued at USD 20 million, share 13.8%, CAGR 7.7%, livestock and poultry testing drive adoption.
• Morocco: Market size USD 10 million, share 6.9%, CAGR 7.6%, expanding veterinary infrastructure supports market growth.

List of Top Veterinary Infectious Disease Diagnostics Companies

• Virbac
• IDEXX Laboratories Inc.
• Innovative Diagnostics
• Biomérieux SA
• Randox Laboratories Ltd
• Qiagen N.V.
• Creative Diagnostics
• Neogen Corporation
• HESKA Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.

IDEXX Laboratories, Inc.: Holds the largest market share globally, with >100,000 veterinary customers and 70+ reference labs performing tens of millions of diagnostic assays yearly.

Biomérieux SA: Ranked second by market penetration, serving 400+ veterinary labs and diagnostic centers.

Investment Analysis and Opportunities

Investment opportunities in the Veterinary Infectious Disease Diagnostics Market include POC molecular platform scale-up, multiplex assay portfolios, surveillance-service contracts, and consumables supply chains. Point-of-care molecular units with run times of 20–90 minutes are high-value capital sells; early movers reported placing thousands of units across clinics and farms. Multiplex panels detecting 4–12 pathogens per assay reduce sample processing costs and increase revenue per sample; reference labs buying these systems sign master supply contracts for tens to hundreds of thousands of tests annually. 

New Product Development

Recent innovations in veterinary infectious diagnostics span rapid molecular POC platforms, high-plex multiplex panels, next-generation sequencing workflows for pathogen discovery, and AI-assisted result interpretation. Several manufacturers launched POC molecular systems that execute sample-to-answer runs in 20–90 minutes, validated for 5–8 companion and production-animal pathogens. Multiplex PCR panels now detect 4–12 respiratory, enteric, and vector-borne agents per run, reducing sample throughput demands by 30–60%. NGS-based pathogen discovery pipelines process dozens to hundreds of samples per run, enabling full-genome characterization useful in outbreak tracing.

Five Recent Developments

• Industry reports estimated the Veterinary Infectious Disease Diagnostics Market at ~USD 2.4–2.7 billion in the recent assessment year, reflecting growth in molecular and POC testing.
• IDEXX published annual filings noting millions of companion-animal diagnostic tests processed across clinic networks and reference lab services in the latest fiscal year.
• Major reference lab networks expanded capacity with automated qPCR instruments, adding throughput of >10,000 assays per week at select sites.
• Rolling national surveillance programs in APAC processed thousands of poultry and swine samples weekly during peak monitoring windows, increasing demand for multiplex assays.
• Several POC molecular platforms achieved regulatory clearances in 5–10 countries between 2023 and 2025, enabling clinic and on-farm deployment at scale.

Report Coverage of Veterinary Infectious Disease Diagnostics Market

This Veterinary Infectious Disease Diagnostics Market Report provides a comprehensive scope: segmentation by diagnostic modality (Immunodiagnostic, Molecular Diagnostic, Others), application channel (Reference Laboratories, Veterinary Clinics, Point-of-Care/In-House Testing, Research Institutes), species focus (companion animals, livestock, poultry, equine), and regional analysis (North America, Europe, Asia-Pacific, Middle East & Africa). 

Veterinary Infectious Disease Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2465.14 Million in 2026
Market Size Value By	USD 4878.42 Million by 2035
Growth Rate	CAGR of 7.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunodiagnostic Molecular Diagnostic Others By Application : Reference Laboratories Veterinary Laboratories and Clinics Point of Care/In House Testing Research Institutes and Universities
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample